NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE204825 Query DataSets for GSE204825
Status Public on Sep 20, 2022
Title Identification of Src Family Kinases as potential therapeutic targets for chemotherapy-resistant triple negative breast cancer
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary Neoadjuvant chemotherapy (NAC) remains the cornerstone of treatment for triple negative breast cancer (TNBC) with the goal of complete eradication of disease. However, for patients with residual disease after NAC, recurrence and mortality rates are high and identification of novel therapeutic targets are urgently needed. Here we quantified tyrosine phosphorylation (pTyr) mediated signaling networks in chemotherapy sensitive (CS) and resistant (CR) TNBC patient derived xenografts (PDX) to gain novel therapeutic insights. We identified Src Family Kinases (SFKs) as potential therapeutic targets in CR TNBC PDXs. Treatment with dasatinib, an FDA approved SFK inhibitor, led to inhibition of tumor growth in vivo. Further analysis of post-treatment PDXs revealed multiple mechanisms of actions of the drug confirming the multi-target inhibition of dasatinib. Direct analysis of pTyr in tumor specimens from TNBC patients suggest a low prevalence of SFK driven tumors in the clinic which may explain why clinical trials evaluating dasatinib failed in unselected breast cancer patients. Taken together, these results underscore the importance of pTyr characterization of tumors in identifying new targets as well as stratifying patients based on their activated signaling networks for therapeutic options. Our data also suggest that treatment with an SFK inhibitor may benefit a subset of TNBC patients with CR disease.
 
Overall design Three to five replicates each of PDXs derived from 4 different PDX lines of triple negative breast cancer were treated with vehicle, paclitaxel, dasatinib or dasatinib+paclitaxel for 21 days. Mice were euthanized when met the euthanization criteria. Tumors were resected and flash frozen. RNA was isolated from the tumor tissues and subjected to RNAseq analysis.
 
Contributor(s) Kohale IN, Yu J, Zhuang Y, Fan X, Boughey JC, Carter JM, Goetz MP, Wang L, White FM
Citation(s) 36077757
Submission date May 25, 2022
Last update date Sep 20, 2022
Contact name Charles Arthur Whittaker
E-mail(s) charliew@mit.edu
Organization name Koch Institute
Street address 77 Mass Ave 76-189
City Cambridge
State/province MA
ZIP/Postal code 02152
Country USA
 
Platforms (1)
GPL18573 Illumina NextSeq 500 (Homo sapiens)
Samples (64)
GSM6195678 BTY14 Vehicle treated replicate 1
GSM6195679 BTY14 Vehicle treated replicate 2
GSM6195680 BTY14 Vehicle treated replicate 3
Relations
BioProject PRJNA842404

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE204825_ikohale_intCt.txt.gz 1.4 Mb (ftp)(http) TXT
GSE204825_ikohale_l2cpm.txt.gz 4.7 Mb (ftp)(http) TXT
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap
External link. Please review our privacy policy.